Suppr超能文献

急性心肌梗死后经皮冠状动脉介入治疗中高剂量冠状动脉内腺苷给药的效果:一项随机对照试验。

Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.

机构信息

Thoraxcenter, Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Circ Cardiovasc Interv. 2009 Aug;2(4):323-9. doi: 10.1161/CIRCINTERVENTIONS.109.858977.109.858977. Epub 2009 Jul 22.

Abstract

BACKGROUND

Coronary microvascular dysfunction is frequently seen in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Previous studies have suggested that the administration of intravenous adenosine resulted in an improvement of myocardial perfusion and a reduction in infarct size. Intracoronary adenosine (bolus of 30 to 60 microg) is a guideline-recommended therapy to improve myocardial reperfusion. The effect of intracoronary adenosine during primary percutaneous coronary intervention has not been investigated in a large randomized trial.

METHODS AND RESULTS

Patients presenting with acute ST-elevation myocardial infarction were randomized to 2 bolus injections of intracoronary adenosine (2 x 120 microg in 20 mL NaCl) or placebo (2 x 20 mL NaCl). The first bolus injection was given after thrombus aspiration and the second after stenting of the infarct-related artery. The primary end point was the incidence of residual ST-segment deviation <0.2 mV, 30 to 60 minutes after percutaneous coronary intervention. Secondary end points were ST-segment elevation resolution, myocardial blush grade, Thrombolysis in Myocardial Infarction flow on the angiogram after percutaneous coronary intervention, enzymatic infarct size, and clinical outcome at 30 days. A total of 448 patients were randomized to intracoronary adenosine (N=226) or placebo (N=222). The incidence of residual ST-segment deviation <0.2 mV did not differ between patients randomized to adenosine or placebo (46.2% versus 52.2%, P=NS). In addition, there were no significant differences in secondary outcome measures.

CONCLUSIONS

In this randomized placebo controlled trial enrolling 448 patients with ST-elevation myocardial infarction, administration of intracoronary adenosine after thrombus aspiration and after stenting of the infarct-related artery did not result in improved myocardial perfusion.

摘要

背景

在经皮冠状动脉介入治疗(PCI)后发生 ST 段抬高心肌梗死的患者中,经常会出现冠状动脉微血管功能障碍。先前的研究表明,静脉内给予腺苷可改善心肌灌注并减少梗死面积。冠状动脉内腺苷(30-60 微克的推注剂量)是改善心肌再灌注的指南推荐治疗方法。在大型随机试验中尚未研究过 PCI 期间冠状动脉内腺苷的作用。

方法和结果

将出现急性 ST 段抬高心肌梗死的患者随机分为两组,分别接受冠状动脉内腺苷(2 x 120 微克,溶于 20 毫升生理盐水)或安慰剂(2 x 20 毫升生理盐水)2 次推注。第一次推注在血栓抽吸后进行,第二次在梗死相关动脉支架置入后进行。主要终点是 PCI 后 30-60 分钟时残留 ST 段偏移<0.2 mV 的发生率。次要终点是 ST 段抬高缓解、心肌染色分级、PCI 后造影上的心肌梗死溶栓治疗(TIMI)血流、酶学梗死面积和 30 天临床结局。共 448 例患者被随机分为冠状动脉内腺苷组(N=226)或安慰剂组(N=222)。随机接受腺苷或安慰剂的患者残留 ST 段偏移<0.2 mV 的发生率无差异(46.2%与 52.2%,P=NS)。此外,次要终点也无显著差异。

结论

在这项纳入 448 例 ST 段抬高心肌梗死患者的随机安慰剂对照试验中,在血栓抽吸后和梗死相关动脉支架置入后给予冠状动脉内腺苷并未改善心肌灌注。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验